[en] Objective: Multiple Sclerosis (MS) is a disease that involves inflammatory demyelination and neurodegeneration of the central nervous system, generating fatigue as one of the main symptoms. The exact etiology of fatigue in MS is unknown, with autoimmune abnormalities, endocrine disorders, mitochondrial dysfunction and a proinflammatory state being attributed as the main causes. There are different studies that relate supplementation with Coenzyme Q10 (CoQ10), a lipid-soluble antioxidant, with benefits in reducing fatigue in various pathologies. The main objective of this study is to determine the effectiveness of the administration of CoQ10 on fatigue in patients diagnosed with MS. Secondary objectives are to estimate the existence of differences in the various types of MS and to evaluate the optimal dose for the treatment of fatigue in MS. Materials and methods: A systematic literature review was conducted based on the PRISMA statement guidelines. The Medline, Embase and Web of Science databases were consulted, including studies with adult patients with fatigue diagnosed with MS who had received the administration of Coenzyme Q10/ubidecarenone as an intervention. Results: A total of 3 studies were obtained, of which 2 are randomized clinical trials and 1 is a non-randomized experimental study. In the different studies, a significant reduction in fatigue was achieved in the intervention group that had received CoQ10 supplementation. In all studies, patients were diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS), and received supplementation with CoQ10 orally for 12 weeks, with variations in the administered dose. Conclusion: The results support the use of CoQ10 supplementation for the reduction of fatigue in RRMS. However, further long-term studies are recommended to confirm the protective effects of CoQ10 on fatigue and clarify the optimal dosage.

[gl] Obxetivos: A Esclerose Múltiple (EM) é unha enfermidade que implica a desmielinización inflamatoria e a neurodexeneración do sistema nervioso central, xerando fatiga como un dos principais síntomas. Descoñécese a etioloxía exacta da fatiga na EM, atribuíndose como causas principais, anomalías autoinmunes, trastornos endócrinos, disfunción mitocondrial e un estado proinflamatorio. Existen diferentes estudos que relacionan a suplementación coa Coenzima Q10 (CoQ10), un antioxidante liposoluble, con beneficios na diminución da fatiga en diversas patoloxías. O obxectivo principal deste estudo é determinar a eficacia da administración de CoQ10 sobre a fatiga en pacientes diagnosticados de EM. Os obxectivos secundarios son estimar a existencia de diferenzas nos distintos tipos de EM e avaliar a dose óptima para o tratamento da fatiga na EM. Metodoloxía: Realizouse unha revisión sistemática da literatura baseándose nas directrices da declaración PRISMA. Consultáronse as bases de datos Medline, Embase e Web of Science, incluíndo estudos con doentes adultos con fatiga diagnosticados con EM que recibiran a administración de coenzima Q10/ubidecarenona como intervención. Resultados: Obtivéronse un total de 3 estudos, dos cales 2 son ensaios clínicos aleatorios e 1 é un estudo experimental non aleatorizado. Nos diferentes estudos conseguiuse unha redución significativa da fatiga no grupo de intervención que recibira suplementación de CoQ10. En todos os estudos, os pacientes foron diagnosticados con Esclerose Múltiple Recurrente-Remitente (EMRR) e recibiron suplementos con CoQ10 por vía oral durante 12 semanas, con variacións na dose administrada. Conclusións: Os resultados apoian o uso da suplementación con CoQ10 para a reducción da fatiga en EMRR. Sen embargo, recoméndase xerar máis estudos a longo prazo para confimar os efectos protectores do CoQ10 na fatiga e establecer a dose óptima.